Home Applications 211349 Application 211349
Type NDA
Sponsor ASTELLAS Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 XOSPATA GILTERITINIB FUMARATE TABLET;ORAL EQ 40MG BASE Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 44 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N211349-001 XOSPATA GILTERITINIB FUMARATE EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28
Orange Book patents# Current patent rows page 1 of 1 · 8 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N211349-001 9487491 2030-07-28 U-2456 2018-12-18 N211349-001 8969336 2032-11-28 Drug substance, Drug product 2018-12-18 N211349-001 10786500 2036-07-01 Drug product 2020-10-28 N211349-001 11938130 2036-07-01 Drug product 2024-04-25 N211349-001 11938131 2036-07-01 Drug product 2024-04-25 N211349-001 11938132 2036-07-01 Drug product 2024-04-25 N211349-001 11938133 2036-07-01 Drug product 2024-04-25 N211349-001 11944620 2036-07-01 Drug product 2024-04-25
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 2 of 2 · 44 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2022-10-28 04:53 UTC 2022-10 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 e64feba35796…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 cb3db0bc1861…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 6 · 218 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-10-15 13:18:30 2026-09 N211349-001 9487491 2030-07-28 U-2456 2018-12-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N211349-001 8969336 2032-11-28 Drug substance, Drug product 2018-12-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N211349-001 10786500 2036-07-01 Drug product 2020-10-28 c2088c7a36db…2026-10-15 13:18:30 2026-09 N211349-001 11938130 2036-07-01 Drug product 2024-04-25 c2088c7a36db…2026-10-15 13:18:30 2026-09 N211349-001 11938131 2036-07-01 Drug product 2024-04-25 c2088c7a36db…2026-10-15 13:18:30 2026-09 N211349-001 11938132 2036-07-01 Drug product 2024-04-25 c2088c7a36db…2026-10-15 13:18:30 2026-09 N211349-001 11938133 2036-07-01 Drug product 2024-04-25 c2088c7a36db…2026-10-15 13:18:30 2026-09 N211349-001 11944620 2036-07-01 Drug product 2024-04-25 c2088c7a36db…2026-09-14 22:38:34 2026-08 N211349-001 9487491 2030-07-28 U-2456 2018-12-18 84e616aacf4f…2026-09-14 22:38:34 2026-08 N211349-001 8969336 2032-11-28 Drug substance, Drug product 2018-12-18 84e616aacf4f…2026-09-14 22:38:34 2026-08 N211349-001 10786500 2036-07-01 Drug product 2020-10-28 84e616aacf4f…2026-09-14 22:38:34 2026-08 N211349-001 11938130 2036-07-01 Drug product 2024-04-25 84e616aacf4f…2026-09-14 22:38:34 2026-08 N211349-001 11938131 2036-07-01 Drug product 2024-04-25 84e616aacf4f…2026-09-14 22:38:34 2026-08 N211349-001 11938132 2036-07-01 Drug product 2024-04-25 84e616aacf4f…2026-09-14 22:38:34 2026-08 N211349-001 11938133 2036-07-01 Drug product 2024-04-25 84e616aacf4f…2026-09-14 22:38:34 2026-08 N211349-001 11944620 2036-07-01 Drug product 2024-04-25 84e616aacf4f…2026-08-18 06:07:40 2026-07 N211349-001 9487491 2030-07-28 U-2456 2018-12-18 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N211349-001 8969336 2032-11-28 Drug substance, Drug product 2018-12-18 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N211349-001 10786500 2036-07-01 Drug product 2020-10-28 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N211349-001 11938130 2036-07-01 Drug product 2024-04-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N211349-001 11938131 2036-07-01 Drug product 2024-04-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N211349-001 11938132 2036-07-01 Drug product 2024-04-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N211349-001 11938133 2036-07-01 Drug product 2024-04-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N211349-001 11944620 2036-07-01 Drug product 2024-04-25 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N211349-001 9487491 2030-07-28 U-2456 2018-12-18 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N211349-001 8969336 2032-11-28 Drug substance, Drug product 2018-12-18 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N211349-001 10786500 2036-07-01 Drug product 2020-10-28 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N211349-001 11938130 2036-07-01 Drug product 2024-04-25 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N211349-001 11938131 2036-07-01 Drug product 2024-04-25 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N211349-001 11938132 2036-07-01 Drug product 2024-04-25 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N211349-001 11938133 2036-07-01 Drug product 2024-04-25 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N211349-001 11944620 2036-07-01 Drug product 2024-04-25 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N211349-001 9487491 2030-07-28 U-2456 2018-12-18 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N211349-001 8969336 2032-11-28 Drug substance, Drug product 2018-12-18 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N211349-001 10786500 2036-07-01 Drug product 2020-10-28 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N211349-001 11938130 2036-07-01 Drug product 2024-04-25 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N211349-001 11938131 2036-07-01 Drug product 2024-04-25 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N211349-001 11938132 2036-07-01 Drug product 2024-04-25 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N211349-001 11938133 2036-07-01 Drug product 2024-04-25 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N211349-001 11944620 2036-07-01 Drug product 2024-04-25 31067a03dcf5…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 2 · 63 observed states.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 5 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 0469-1425 Xospata gilteritinib Astellas Pharma US, Inc. NDA Current 0469-1425 Xospata gilteritinib Astellas Pharma US, Inc. NDA Current 0469-1425 Xospata gilteritinib Astellas Pharma US, Inc. NDA Current 0469-1425 Xospata gilteritinib Astellas Pharma US, Inc. NDA Current 0469-1425 Xospata gilteritinib Astellas Pharma US, Inc. NDA Current
Documents# Document, Submission type, Date table Document Submission type Date 69874 SUPPL 2022-01-13 69873 SUPPL 2022-01-13 69868 SUPPL 2022-01-13 64574 SUPPL 2020-09-14 58934 SUPPL 2019-06-04 58880 SUPPL 2019-05-30 58879 SUPPL 2019-05-30 56985 ORIG 2018-12-21 56610 ORIG 2018-11-30 56581 ORIG 2018-11-28